GlassScriptPhysician profile
Yufei Tang
NPI 1093150161
$11,251.37
in general payments reported to CMS, 2019-2025
30 companies · $1,783 in 2025
The $1,783 reported for 2025 was more than what 82% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $134 · 2020: $1,237 · 2021: $2,369 · 2022: $2,000 · 2023: $1,740 · 2024: $1,989 · 2025: $1,783.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,511.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,511.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,308.84 | 2020-2025 | Repatha, Repatha |
| Astrazeneca Pharmaceuticals LP | $1,142.62 | 2020-2025 | Farxiga, Brilinta |
| Pfizer INC. | $912.35 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $816.90 | 2020-2025 | |
| Abbott Laboratories | $811.50 | 2020-2024 | Jot Dx, Mitraclip |
| Boehringer Ingelheim Pharmaceuticals, INC. | $806.46 | 2020-2025 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $703.57 | 2020-2025 | Eliquis, Camzyos |
| Merck Sharp & Dohme LLC | $618.32 | 2021-2025 | Verquvo |
| Novo Nordisk INC | $545.02 | 2021-2025 | Ozempic, Wegovy, Rybelsus |
| Janssen Pharmaceuticals, INC | $446.77 | 2021-2024 | Xarelto |
| Esperion Therapeutics, INC. | $422.43 | 2021-2025 | Nexletol |
| Lexicon Pharmaceuticals, INC. | $397.12 | 2023-2024 | Inpefa |
| Sanofi-Aventis U.S. LLC | $362.72 | 2021-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $324.65 | 2021-2025 | |
| Edwards Lifesciences Corporation | $315.58 | 2020-2025 | Sapien 3 Ultra Resilia |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $306.56 | 2021-2023 | Watchman Flx |
| Amarin Pharma, INC. | $272.53 | 2020-2022 | |
| Scpharmaceuticals INC. | $165.63 | 2023-2025 | |
| Kiniksa Pharmaceuticals International, Plc | $104.38 | 2024 | Arcalyst |
| Shockwave Medical, INC | $97.07 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $88.44 | 2020-2022 | |
| Celgene Corporation | $75.84 | 2023 | Camzyos |
| Lilly USA, LLC | $50.78 | 2025 | Zepbound |
| Alnylam Pharmaceuticals INC. | $43.58 | 2021 | |
| Tactile Systems Technology INC | $25.75 | 2024 | Flexitouch Plus, Entre Plus |
| Bridgebio Pharma, INC. | $20.17 | 2025 | Attruby |
| Amryt Pharma Holdings LTD | $18.99 | 2021 | |
| Heartflow, INC. | $16.64 | 2023 | Ffrct |
| Kiniksa Pharmaceuticals, LTD. | $15.10 | 2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $15.06 | 2025 | Lifevest |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yufei Tang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.